Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
  • Platform
  • Pipeline
  • Clinical Trials
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Connect

Press Releases

To view the webinar replay of “PRECISE-AD Phase 1b Blinded Interim Data Analysis"  Click Here

News & Media

News & Media

  • Press Releases
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Sep 13, 2017

ProMIS Neurosciences Designates PMN330 as Third, Validated Lead Product for Development in Alzheimer's Disease

Aug 28, 2017

ProMIS Neurosciences Completes Second Closing of Private Placement

Aug 11, 2017

ProMIS Neurosciences Announces Second Quarter 2017 Results

Jul 5, 2017

ProMIS Neurosciences to Present Preclinical Data from Alzheimer's Disease Program at AAIC 2017

Jun 6, 2017

ProMIS™ Neurosciences Appoints William C. Mobley to Scientific Advisory Board

May 31, 2017

ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia

May 25, 2017

Prion 2017: Deciphering Neurodegenerative Disorders - 23-26 May 2017 Edinburgh

May 24, 2017

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer's Disease

  • arrow_back
  • 1…
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
Linkedin Twitter
©2026 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy

Disclaimer

All statements and expressions are the sole opinion of the company and are subject to change without notice.  The Company is not liable for any investment decisions by its readers or subscribers.  It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies.  The information contained herein has been provided as an information service only.  The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained.  Investors are cautioned that they may lose all or a portion of their investment in this or any other company.

Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.  Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements".  Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.